Stockreport

Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF - Up to 97% reduction in intra-hepatic Z-AAT polymer- Up to 95% reduction in intra-hepatic total Z-AAT burden- Up to 66% and 58% reduction in circulating ALT and GGT lev [Read more]